FDA Inspection Classifications for Compounders: NAI, VAI and OAI

FDA closes nearly every compounding pharmacy or outsourcing facility inspection with one of three outcomes: No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI). The classification rarely appears in plain language in the letter a facility gets right after the investigator leaves, and compounders often do not learn which one applies until weeks or months later. The stakes ride on which one FDA picks: an OAI determination is the gateway to a warning letter, a state board referral, and for a registered outsourcing facility, the loss of its 503B registration.

What NAI, VAI and OAI Mean

FDA defines the three classifications the same way across every regulated industry it inspects, compounding included. No Action Indicated means the facility is in an acceptable state of compliance, and FDA usually does not issue a Form 483 at all. Voluntary Action Indicated means the inspection found objectionable conditions, but FDA has concluded the facility can correct them voluntarily, without the agency recommending any action. Official Action Indicated means FDA considers the facility in an unacceptable state of compliance, and the conditions are serious enough that the agency generally recommends regulatory or administrative action. A Form 483 may be issued at the close of an OAI inspection, listing the specific observations the investigator believes support that conclusion.

From Form 483 to Final Classification

A Form 483 is the investigator's list of observations, issued at the end of the inspection before FDA's compliance staff have reviewed anything, not the classification itself. HLA's comparison of a Form 483 and a warning letter walks through how the two documents differ and what each one does and does not establish. FDA encourages facilities to respond in writing within 15 business days of a Form 483's issuance, and the agency says it weighs that response, together with the full inspection record, before settling on a classification. A facility's final classification letter is usually sent within 45 to 90 days after the inspection closes, depending on the inspection type, which means a compounding pharmacy or outsourcing facility can operate for months without knowing officially whether FDA landed on VAI or OAI.

What an OAI Classification Puts at Risk

FDA's own enforcement record for compounding facilities shows where an OAI-classified inspection goes next. A warning letter is one action FDA may take once an inspection is classified OAI, and the agency's compliance reviewers write it after the inspection closes, not in the field. For a traditional 503A pharmacy, FDA also sends a referral letter to the state board of pharmacy, the body that actually licenses the pharmacy, since FDA itself does not. For a registered 503B outsourcing facility, the escalation can reach the registration itself. FDA's compounding enforcement record documents outsourcing facilities deregistering after an OAI-classified inspection, which ends the facility's ability to compound under the 503B exemption.

The findings that can support an OAI call track the same operational gaps compounders see cited elsewhere: deficient cGMP documentation, sterile and hazardous compounding gaps under USP 797/800, and unsupported beyond-use dating. Serious or repeated findings that go uncorrected can also support an injunction or a product seizure, in addition to the warning letter and referral paths described above.

An OAI classification is FDA's own conclusion that the facility's compliance is unacceptable, which is why the facility's written response before that letter arrives matters more than anything filed after it.

Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.

Why Early Legal Counsel Is Critical

Compounding pharmacies and outsourcing facilities should retain healthcare defense counsel as soon as an FDA investigator opens an inspection, not after the classification letter arrives weeks or months later. Counsel can shape the written response to a Form 483 while FDA's compliance staff are still weighing it, correct the factual record while the matter remains open, and intervene before an OAI determination hardens into a warning letter, a state board referral, or a lost 503B registration.

How Health Law Alliance Can Help

Health Law Alliance's FDA regulatory compliance attorneys represent compounding pharmacies and outsourcing facilities through FDA inspections, Form 483 responses, and the classification process that follows. Contact us today for a free, confidential consultation.